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ABSTRACT: Epidermal growth factor receptor tyrosine kinase inhibitors represent a new
treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This
retrospective study examined to what extent previous clinical trial experience matches large-
scale Western community implementation of this treatment.
In the Belgian expanded access programme, the data from 513 patients with advanced or
metastatic NSCLC, not suitable for further chemotherapy and receiving oral gefitinib 250 mg?day-1
until disease progression, death or unacceptable toxicity, were analysed.
The median (range) duration of gefitinib treatment was 2.3 months (0.0–32.7). Its use was
predominantly in second- or third-line treatment. The overall response and disease control rates
were 8.9 and 41.2%, respectively. In univariate analysis, response was more common in females
and never-smokers. In multivariate analysis, female sex was the only significant predictive factor
(odds ratio (OR) (95% confidence interval (CI)) 0.329 (0.129–0.839)). Symptom improvement was
reported in 108 patients of whom 32 (29.6%) had an objective response, 66 (61.1%) experienced
disease stabilisation and 10 (9.3%) progressed. Gefitinib was well tolerated; only 7.8% of the
patients reported grade 3 or 4 toxicity. The overall median survival was 4.7 months, with a 1-yr
survival rate of 21%. Survival was strongly influenced by a better performance status (PS) (good
PS: hazard ratio (HR) (95%CI) 0.110 (0.077–0.157)) and adenocarcinoma with bronchioloalveolar
carcinoma features histology (HR (95%CI) 0.483 (0.279–0.834)).
In conclusion, the activity of gefitinib was confirmed in the present large Western community
implementation study. Response, present in a small subgroup, led to a rewarding survival and
could be predicted by sex only. Baseline performance status and adenocarcinoma with
bronchioloalveolar carcinoma features histology were significant factors for survival.
KEYWORDS: Community implementation study, epidermal growth factor, expanded access,
gefitinib, nonsmall cell lung cancer, treatment outcome
T
he treatment of advanced nonsmall cell
lung cancer (NSCLC) has improved over
the past decade. Cisplatin-based che-
motherapy improves the outcome of patients
with early [1] or locally advanced NSCLC [2]. In
metastatic disease, modern regimens combining
platinum with gemcitabine or taxanes have
brought the 1-yr survival rate from 15 to 30%.
However, a therapeutic plateau has been reached
with the current chemotherapeutic options.
Furthermore, better options for patients who
relapse after first- and second-line chemotherapy
are needed [3]. Consequently, targeted therapy
gained a central place in current cancer thera-
peutics development. The most striking example
is the success of imatinib in the treatment of
gastrointestinal stromal tumours [4]. As NSCLC
is characterised by frequent expression of the
epidermal growth factor receptor (EGFR), this
target was studied extensively. Based on the
results of two randomised phase II studies (Iressa
Dose Evaluation in Advanced Lung Cancer
(IDEAL) 1 and 2) showing encouraging response
and symptom improvement rates in heavily pre-
treated patients, the EGFR tyrosine kinase inhi-
bitor (TKI) gefitinib became the first available
targeted therapy for the treatment of NSCLC [5,
6]. Gefitinib was approved for the treatment of
relapsed NSCLC in several countries, including
Japan and the USA. In the meanwhile, no
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additional benefit could be demonstrated when gefitinib was
added to standard first-line chemotherapy in the Iressa NSCLC
Trial Assessing Combination Treatment (INTACT) studies [7,
8]. In the phase III Iressa Survival Evaluation in Lung Cancer
(ISEL) study in patients failing after previous chemotherapy,
gefitinib improved survival compared to best supportive care
alone. However, this difference did not reach significance
except in pre-defined subgroups, such as never-smokers or
Asian patients [9].
In a worldwide Expanded Access Program (EAP), patients
with advanced NSCLC and no alternative therapeutic options
were able to receive gefitinib treatment. As a variable degree of
selection is always present in the context of prospective clinical
trials, it is important to study the applicability of their results
in community settings. The present study represents the
retrospective analysis of the patients enrolled in the EAP in
Belgium. The purpose of the analysis is to examine the
response and outcome with gefitinib and the tolerability
within the general community setting as well as to identify
clinical parameters that may predict for response or survival.
In an ancillary study, a set of genetic parameters that could




Patient data were retrieved from the Belgian EAP, which
involved a total of 1,464 patients enrolled between January
2001 and December 2004. All patients with proven advanced
NSCLC failing previous chemotherapy or without alternative
therapeutic options were able to receive gefitinib 250 mg?day-1
until disease progression, death or unacceptable toxicity
occurred. Inherent to this type of study, response assessment
was not prospectively structured according to, for example,
Response Evaluation Criteria in Solid Tumours (RECIST)
parameters, but performed at each centre according to local
standards. In general, a first evaluation of response with
clinical factors [10], chest radiography and/or computed
tomography scan took place after 4-6 weeks of treatment.
Symptom improvement (SI) was evaluated according to the
clinical judgement of the treating physician. All participating
patients gave written informed consent. All centres that had
o10 patients in the EAP participated in the present study,
except for one refusal in a centre with 14 cases. A standardised
questionnaire listing data on demographics, tolerability,
response, symptom improvement and outcome was used to
sample the data. Baseline assessment included smoking
history, World Health Organization (WHO) performance
status (PS), tumour assessment and previous local therapy
(surgery or radiotherapy). Detailed information about previous
chemotherapy was included, i.e. number of lines, drugs
administered, duration of treatment, treatment-free intervals
and best objective response to each line.
Statistics
Descriptive data are presented as median (range). The
relationship between patients’ characteristics and likelihood
of response, disease control (i.e. response or stabilisation) or
symptom improvement were tested using a Chi-squared test
in the univariate analysis and logistic regression in the
multivariate analysis. The variables of interest were sex,
performance status, smoking history, histology and number
of lines of prior chemotherapy. Overall survival was defined as
the period between the start of gefitinib treatment and the date
of last follow-up for censored cases or date of death. For
survival, the same set of variables was studied. The relation-
ship with survival was studied with the Kaplan-Meier analysis
and log-rank test and with Cox regression for multivariate
analysis. A p-value ,0.05 was considered to be statistically
significant.
RESULTS
Data from 513 patients were retrieved from different academic
(six centres, 267 patients) and nonacademic (five centres, 246
patients) hospitals.
The patients’ demographics are listed in table 1. Male and
stage IV subgroups were ,75% of the total number of patients
each. There were 40 (7.8%) never-smokers and 34 (6.7%)
patients with adenocarcinoma with bronchioloalveolar carci-
noma features (AD/BAC). Almost 60% of the patients had
received o2 lines of chemotherapy before entering the EAP
with gefitinib. This chemotherapy mostly consisted of plati-
num (81.5%), gemcitabine (71.4%) or vinorelbine (30.2%), and a
taxane (50.7%), as currently accepted first- and second-line
treatment. Gefitinib was used as primary treatment in patients
non amenable to chemotherapy due to low PS, comorbidity or
refusal. The median (range) duration of gefitinib treatment was
2.3 months (0.0–32.7) in the total group.
The overall observed response rate (RR) was 8.9%, with four
complete responders (table 2). The median (range) duration of
intake of gefitinib in responders was 8.1 months (1.9–25.4),
with 13 patients still taking gefitinib at the time of analysis. The
RR was significantly higher in females compared with males
(16.2 versus 6.2%, p50.002) and lifetime never-smokers
compared with ever-smokers (21.8 versus 8.0%, p50.009).
The overall observed disease control rate (DCR) was 41.2%.
The median (range) duration of intake of gefitinib in these
patients was 6.8 months (0.6–32.7) with 21 patients still taking
gefitinib at the time of analysis. DCR correlated significantly
with a better PS (good versus intermediate versus poor: 55.7
versus 36.7 versus 12.5%; p,0.0001), number of previous
chemotherapy regimens (none versus one versus two: 60.0
versus 48.1 versus 34.9%; p50.004) and with AD/BAC histology
compared to non-AD/BAC histology (60.0 versus 39.9%,
p50.049).
In the multivariate analysis, likelihood of response was
significantly determined by female sex (odds ratio (OR) (95%
confidence interval (CI)) 0.329 (0.129–0.839), p50.020). For
disease control the only significant factor was a good PS (OR
(95%CI) 0.105 (0.035–0.320), p,0.0001). A never-smoking
history was nonpredictive.
In patients for whom sufficient symptom data were available
(unknown in 118 patients), 29% (108 patients) experienced an
improvement in overall symptoms. Of these, 32 (29.6%) had an
objective response, 66 (61.1%) experienced disease stabilisation
and 10 (9.3%) progressed. In univariate analysis, there was a
statistically significant association between SI and PS (good
versus intermediate versus poor: 40.3 versus 22.5 versus 7.5%;
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p,0.0001) and AD/BAC histology (AD/BAC versus non-AD/
BAC, 73.7 versus 26.8%; p50.048), but not with sex or smoking
status.
The median overall survival time (MST) after the start of
treatment with gefitinib was 4.7 months, with a 1-yr survival
rate (1YSR) of 21% (table 3). Figure 1 shows the Kaplan-Meier
estimates of overall survival comparing patients with good,
intermediate or poor PS (p,0.0001). Other factors associated
with better survival rates were AD/BAC histology (p50.033)
(fig. 2) and the number of prior chemotherapy treatments
(p50.013). In the multivariate Cox regression, better PS (good
PS: HR (95%CI) 0.110 (0.077–0.157), p,0.0001; and intermedi-
ate PS: HR (95%CI) 0.283 (0.202–0.396), p,0.0001) and AD/
BAC histology (HR (95%CI) 0.483 (0.279–0.834), p50.009)
remained significant predictive factors for survival.
The favourable tolerability of gefitinib was confirmed: only
7.8% of the patients were reported with grade 3 or 4 toxicity. A
serious adverse event of pulmonary nature was reported in
eight of the 513 patients. Five of these belonged to another
category: cardiogenic pulmonary oedema (n51), diffuse
progression of tumour with bronchioloalveolar features
(n51), infectious pneumonia (n52) and infectious pneumonia
plus pulmonary embolism (n51). Three instances of interstitial
lung disease (ILD) were reported. One of these was unlikely to
be related to gefitinib, as the ILD occurred 13 months after
discontinuation of gefitinib. Two others were probably related,
occurring 31 and 33 days after the start of gefitinib treatment,
respectively. In both patients, other causes of ILD were ruled
out. Both improved with cessation of gefitinib and adminis-
tration of corticosteroids.
DISCUSSION
This retrospective analysis of the treatment with gefitinib for
advanced NSCLC in a mixed academic and nonacademic
setting in the Belgian EAP demonstrated clear antitumour
activity (RR 8.9%; DCR 41.2%) in the absence of major toxicity
(grade 3 or 4 toxicity 7.8%). The median duration of intake of
gefitinib was 8.1 months in responding patients and
6.8 months in patients with disease stabilisation. Although
the present authors do not really have the exact time to
progression based on rigorous radiological follow-up, the
results suggest a clinically meaningful duration of the effect of
gefitinib in many patients. Symptom improvement was
reported in 29.0% of the patients. As a whole, the findings in
this large Western community implementation study demon-
strate that the findings from previous prospective clinical trials
[5, 6] are reproducible in a probably less selected group of
patients coming from daily practice.
In the multivariate analysis, only female sex could be retained
as a predictive factor for activity, but not histology or smoking
status. Based on prospective trials and retrospective series,
Asian origin, never-smoking status, adenocarcinoma histology
and female sex are the most often reported predictors of
response [5, 11–15]. Ethnicity was not a factor in the present
series, as all patients were Caucasians. The never-smoking
status of lung cancer patients is probably the strongest
indicator of activity in Western populations [9, 11, 12, 15, 16].
This factor was significant in the current univariate analysis
(p50.009), but was not withheld in the multivariate analysis
probably due to the lower number of known never-smokers in
the series or due to overlap with other clinical factors. The RR
was similar in patients with adenocarcinoma compared with
nonadenocarcinoma (9.4 versus 8.4%) and AD/BAC compared
with non-AD/BAC histology (12.0 versus 8.7%). This is in
contrast with most other studies, where adenocarcinoma
histology, especially the AD/BAC subtype, is usually asso-
ciated with higher likelihood of response [11–13, 17]. The fact
that different centres and, as such, different pathologists
participated in the present study may be a factor in this
apparent discrepancy. Nevertheless, responses in patients with
squamous cell carcinoma were also reported in a recent large
phase III study with the EGFR-TKI erlotinib [16].
A correlation was also found between PS and activity of gefitinib.
As patients with a very low performance status (3 or 4) are in
TABLE 1 Demographics of the study patients
Characteristics









Good (0–1) 191 (37.3)
Intermediate (2) 133 (25.9)









Squamous cell 135 (26.3)














Data are presented as median (range) and n (%), unless otherwise stated.
WHO: World Health Organization; AD/BAC: adenocarcinoma with bronchio-
loalveolar features; NSCLC: nonsmall cell lung cancer.
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general not considered for chemotherapy, the issue has been
raised whether this group could benefit from better-tolerated
targeted therapies like gefitinib. These patients were, however,
excluded from the prospective trials with gefitinib. The activity of
gefitinib was poor in the present low PS population, suggesting
that they are unlikely to benefit from this therapy, but as there
was no comparator arm in the present study, it is not possible to
ascertain that there would not be a benefit over best supportive
care alone in such patients.
TABLE 2 Univariate analysis of predictive factors for response or disease stabilisation#
Patients n Responders n RR % p-value DC patients n DCR % p-value
All patients 403 36 8.9 166 41.2
Sex 0.002 0.950
Female 111 18 16.2 46 41.4
Male 292 18 6.2 120 41.1
WHO performance status 0.098 ,0.0001
0–1 176 19 10.8 98 55.7
2 98 5 5.1 36 36.7
3–4 40 1 2.5 5 12.5
Smoking status 0.009 0.145
Never-smoker 32 7 21.9 17 53.1
Smoker 351 28 8.0 140 39.9
Histology 0.728 0.578
Adenocarcinoma 224 21 9.4 95 42.4
Nonadenocarcinoma 179 15 8.4 71 39.7
Histology 0.579 0.049
AD/BAC 25 3 12.0 15 60.0
Non-AD/BAC 378 33 8.7 151 39.9
Prior chemotherapy regimens 0.295 0.004
0 30 4 13.3 18 60.0
1 135 15 11.1 65 48.1
o2 238 17 7.1 83 34.9
RR: response rate; DC: disease control; DCR: disease control rate; WHO: World Health Organization; AD/BAC: adenocarcinoma with bronchioloalveolar features. #:
totals and subtotals can be lower than expected in certain cells due to missing values.





All patients 513 4.7 21.4
Sex 0.123
Female 141 5.7 26.8
Male 372 4.7 19.3
WHO performance status ,0.0001
0–1 191 8.0 36.3
2 133 2.9 10.0
3–4 73 1.1 0.0
Smoking status 0.283
Never-smoker 40 7.3 25.2
Smoker 448 4.6 20.3
Histology 0.429
Adenocarcinoma 286 4.9 24.4
Nonadenocarcinoma 227 4.6 17.4
Histology 0.033
AD/BAC 34 8.9 39.1
Non-AD/BAC 479 4.5 20.3
Prior chemotherapy regimens 0.013
0 42 8.0 27.0
1 170 5.3 26.1
o2 301 3.8 16.4
MST: median survival time; 1YSR: 1-yr survival rate; WHO: World Health
Organization; AD/BAC: adenocarcinoma with bronchioloalveolar features. #: totals






















FIGURE 1. Survival according to the performance status (PS) at the start of
gefitinib treatment. ——: PS 0-1; ------: PS 2; ..........: PS 3-4.
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The MST of the total group was 4.7 months after the start of
treatment with gefitinib, with a 1YSR of 21%. This is somewhat
inferior to the survival data in the IDEAL studies [5, 6],
probably due to a lower degree of patient selection in the
present implementation study, as can be illustrated by the
inclusion of 73 patients with very poor PS. This subgroup
performed very badly, with a MST of only 1.1 month. The
importance of PS for outcome has been reported by others as
well [11, 14, 17, 18]. Apart from PS, AD/BAC histology was
retained as a predictor of survival in the multivariate analysis.
The longer MST of the patients with AD/BAC in the present
series is probably an indicator of the more indolent course of
this special type of NSCLC [19].
A favourable outcome in a subpopulation of NSCLC patients
who respond to gefitinib was observed. Some responding
patients experienced long-term benefit of the treatment, as can
be suggested from the median duration of gefitinib treatment
of 8.1 months in responders, up to a total of .2 yrs in a few
patients. It is, however, urgently needed to have unequivocal
predictors of activity of this important targeted agent for
NSCLC. As it is obvious from the present community series
and the experience of others, the ‘‘clinical’’ predictors of
response are not well established in Western populations, with
the exception of a never-smoking status in some series [9, 16].
Better and more targeted use of agents such as gefitinib is
clearly needed to bring this breakthrough in the treatment of
NSCLC to those patients who really benefit in a way that can
be afforded by the health security systems. Increasing the
understanding of the mechanism of action of these agents and
deriving an unequivocal and specific predictive test from this
knowledge is the way forward. At the present moment, such a
test is not available for clinical practice. Expression of EGFR on
the cell surface, measured by grading immunohistochemical
staining with an EGFR antibody, is in general poorly predictive
for a response [20, 21]. A frequent occurrence of EGFR domain
mutations, reported in responders to EGFR-TKIs [22, 23], could
not be confirmed in a recent phase III study [16]. The presence
of a high EGFR gene copy number identified by fluorescence in
situ hybridisation may become the most promising molecular
predictor for gefitinib efficacy in NSCLC [24]. Further
molecular analysis in the group of patients from the present
series is ongoing.
The strengths of the present study are: the fact that it
represents a large sample of patients of both university-
affiliated and community hospitals from across the country,
the collection of data during a defined time window and the
use of a standardised data collection tool. The present study
also has several potential limitations. The inclusion of some
chemo-naive patients in the EAP for reasons of poor PS or
comorbidity was allowed, despite the fact that this did not
correspond to standard treatment guidelines. Less structured
or less detailed documentation of patient data in the medical
record is inherent to all retrospective chart audits, like the
present implementation study.
Finally, it was not the aim of the present authors to measure
safety and toxicity in detail, as this had already been
performed in prospective series [5–8]. The data query sheet
used only asked for the severe toxicity (grade 3 or 4 according
to the National Cancer Institute Common Toxicity Criteria)
occurring during gefitinib treatment. No further information
on lower grade toxicity was asked in order to avoid the use of a
too complex sheet for several nonacademic centres. One side-
effect, drug-induced ILD is, however, of particular concern due
to its potential severity, especially in Asian patients [25]. Most
probably, the incidence in Western populations is only slightly
elevated. In a large phase III study, an incidence of ILD of 1.5%
for patients taking gefitinib 250 mg?day-1 and 0.9% for patients
taking placebo was reported, a difference of 0.6% [8]. In
another phase III study, the overall incidence of ILD-type
events was ,1% [7]. In the present series, which is one of the
largest EAPs with a pure Caucasian population, no serial
pulmonary function tests were in place, but clinically relevant
ILD probably related to gefitinib could be withheld in two
instances (0.4%). Both patients recovered with cessation of the
drug and corticosteroid medication.
In summary, the present large Western community imple-
mentation study of gefitinib for advanced nonsmall cell lung
cancer confirmed the good tolerability of this agent. Response,
present in a subpopulation, led to very rewarding survival
outcomes. Clinically meaningful symptom improvement was
linked to disease response and disease stabilisation. Response
could be predicted by sex only. Better predictive tests of
activity of gefitinib are urgently needed to allow us to offer this
therapy in a true targeted approach to those nonsmall cell
lung cancer patients who would really benefit from this
therapy while keeping the expenses for society at an acceptable
level.
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FIGURE 2. Survival according to adenocarcinoma with bronchioloalveolar
features (AD/BAC; ——) or non-AD/BAC (..........) histology.
GEFITINIB FOR ADVANCED NSCLC R. VAN PUIJENBROEK ET AL.
132 VOLUME 29 NUMBER 1 EUROPEAN RESPIRATORY JOURNAL
REFERENCES
1 Arriagada R, Bergman B, Dunant A, Le Chevalier T,
Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-
small-cell lung cancer. N Engl J Med 2004; 350: 351–360.
2 Rowell NP, O’Rourke NP. Concurrent chemoradiotherapy
in non-small cell lung cancer. Cochrane Database Syst Rev
2004; 4: CD002140.
3 Massarelli E, Andre F, Liu DD, et al. A retrospective
analysis of the outcome of patients who have received two
prior chemotherapy regimens including platinum and
docetaxel for recurrent non-small-cell lung cancer. Lung
Cancer 2003; 39: 55–61.
4 Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and
safety of imatinib mesylate in advanced gastrointestinal
stromal tumors. N Engl J Med 2005; 347: 472–480.
5 Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional
randomized phase II trial of gefitinib for previously treated
patients with advanced non-small cell lung cancer (The
IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–2246.
6 Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefinitib,
an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell
lung cancer: a randomized trial. JAMA 2003; 290: 2149–2158.
7 Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in
combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial (INTACT 1). J
Clin Oncol 2004; 22: 777–784.
8 Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in
combination with paclitaxel and carboplatin in advanced
non-small-cell lung cancer: a phase III trial (INTACT 2). J
Clin Oncol 2004; 22: 785–794.
9 Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best
supportive care in previously treated patients with
refractory advanced non-small cell lung cancer: results
from a randomised, placebo-controlled, multicentre study
(Iressa Survival Evaluation in Lung Cancer). Lancet 2005;
366: 1527–1537.
10 Therasse P, Arbuck SG, Eisenhauer EA, et al. New
guidelines to evaluate the response to treatment in solid
tumours. J Natl Cancer Inst 2000; 92: 205–216.
11 Haringhuizen A, Van Tinteren H, Vaessen HF, Baas P, Van
Zandwijk N. Gefitinib as a last treatment option for non-
small-cell lung cancer: durable disease control in a subset
of patients. Ann Oncol 2004; 15: 786–792.
12 Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar
pathologic subtype and smoking history predict sensitivity
to gefitinib in advanced non-small-cell lung cancer. J Clin
Oncol 2004; 22: 1103–1109.
13 Konishi J, Yamazaki K, Kinoshita I, et al. Analysis of the
response and toxicity to gefitinib of non-small cell lung
cancer. Anticancer Res 2005; 25: 435–441.
14 Lim ST, Wong EH, Chuah KL, et al. Gefitinib is more
effective in never-smokers with non-small-cell lung cancer:
experience among Asian patients. Br J Cancer 2005; 93: 23–28.
15 Veronese ML, Algazy K, Bearn L, et al. Gefitinib in patients
with advanced non-small cell lung cancer (NSCLC): the
expanded access protocol experience at the University of
Pennsylvania. Cancer Invest 2005; 23: 296–302.
16 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.
Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med 2005; 353: 123–132.
17 Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839)
monotherapy as a salvage regimen for previously treated
advanced non-small cell lung cancer. Clin Cancer Res 2004;
10: 4383–4388.
18 Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and
tolerability of gefitinib in pretreated elderly patients with
advanced non-small cell lung cancer (NSCLC). Br J Cancer
2004; 90: 82–86.
19 Miller VA, Hirsch FR, Johnson DH. Systemic therapy of
advanced bronchioloalveolar cell carcinoma: challenges
and opportunities. J Clin Oncol 2005; 23: 3288–3293.
20 Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal
growth factor receptor expression as a predictive factor for
response to gefitinib (‘‘Iressa’’, ZD1839) in non-small-cell
lung cancer. Br J Cancer 2004; 91: 208–212.
21 Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane
staining is not clinically relevant for predicting response in
patients receiving gefitinib (‘‘Iressa’’, ZD1839) monother-
apy for pretreated advanced non-small cell lung cancer:
IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44: 170A.
22 Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung
cancer: correlation with clinical response to gefitinib
therapy. Science 2004; 304: 1497–1500.
23 Lynch TJ, Bell DW, Sordella R, et al. Activating mutations
in the epidermal growth factor receptor underlying
responsiveness of non-small cell lung cancer to gefitinib.
N Engl J Med 2004; 350: 2129–2139.
24 Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth
factor receptor gene and protein and gefitinib sensitivity in
non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643–
655.
25 Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial
pneumonia and gefitinib. Lancet 2003; 361: 137–139.
R. VAN PUIJENBROEK ET AL. GEFITINIB FOR ADVANCED NSCLC
EUROPEAN RESPIRATORY JOURNAL VOLUME 29 NUMBER 1 133
